Efficacy and Safety of Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two, Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-Week Induction Trials (Abtect-1 and 2)

Authors
Category Primary study
ConferenceInflammatory Bowel Disease (IBD) Conference
Year 2025
This article has no abstract
Epistemonikos ID: 8e8064581cc917f7d86ed187fd2ea16029905e77
First added on: Dec 19, 2025